Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Zilucoplan in Pediatric Study Participants With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis

NCT06435312 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT06435312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06435312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Zilucoplan in Pediatric Study Participants With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis
Lead sponsor
UCB Biopharma SRL
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
November 19, 2024
Completion date
November 19, 2027
Enrollment
8 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

generalized myasthenia gravis